Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Circassia Pharmaceuticals ( (GB:NIOX) ) just unveiled an update.
NIOX Group plc, a company operating in the pharmaceutical industry, announced that its Chief Financial Officer, Sarah Duncan, has purchased 5,522 Ordinary Shares at a price of 70.64 pence per share. This transaction, which took place on December 3, 2025, represents a minor increase in her shareholding, now totaling 0.001% of the company’s issued share capital. The purchase signifies confidence in the company’s future prospects and may positively influence investor sentiment.
The most recent analyst rating on (GB:NIOX) stock is a Hold with a £76.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals’ overall stock score is driven primarily by its strong financial performance, characterized by robust revenue growth and cash flow management. The technical analysis indicates a positive trend, though momentum is limited. The high P/E ratio suggests potential overvaluation, partially offset by a decent dividend yield.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
Average Trading Volume: 1,009,796
Technical Sentiment Signal: Buy
Current Market Cap: £296.7M
See more data about NIOX stock on TipRanks’ Stock Analysis page.